103 related articles for article (PubMed ID: 2592776)
21. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
[TBL] [Abstract][Full Text] [Related]
22. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins.
Breloer M; Fleischer B; von Bonin A
J Immunol; 1999 Mar; 162(6):3141-7. PubMed ID: 10092763
[TBL] [Abstract][Full Text] [Related]
23. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
[TBL] [Abstract][Full Text] [Related]
24. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis.
Ratner A; Clark WR
J Immunol; 1993 May; 150(10):4303-14. PubMed ID: 8482837
[TBL] [Abstract][Full Text] [Related]
25. Natural cytotoxic activity in a cloned natural killer cell line is mediated by tumor necrosis factor.
Richards AL; Dennert G; Pluznik DH; Takagaki Y; Djeu JY
Nat Immun Cell Growth Regul; 1989; 8(2):76-88. PubMed ID: 2761550
[TBL] [Abstract][Full Text] [Related]
26. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
[TBL] [Abstract][Full Text] [Related]
27. Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity.
Fisk B; Ioannides CG
Cancer Res; 1998 Nov; 58(21):4790-3. PubMed ID: 9809978
[TBL] [Abstract][Full Text] [Related]
28. Constitutive expression of tumor necrosis factor-alpha in cytotoxic cells of teleosts and its role in regulation of cell-mediated cytotoxicity.
Praveen K; Evans DL; Jaso-Friedmann L
Mol Immunol; 2006 Feb; 43(3):279-91. PubMed ID: 16199264
[TBL] [Abstract][Full Text] [Related]
29. TNF-alpha is not the sole mediator of WEHI-164 tumour cell killing in natural cytotoxicity.
Clarke GR; Shirzadeh H; Pang G; Beagley KW; Burton RC; Smart YC
Cytokine; 1997 Apr; 9(4):254-62. PubMed ID: 9112334
[TBL] [Abstract][Full Text] [Related]
30. Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule.
Lu Y; Yamauchi N; Koshita Y; Fujiwara H; Sato Y; Fujii S; Takahashi M; Sato T; Kato J; Yamagishi H; Niitsu Y
Gene Ther; 2001 Apr; 8(7):499-507. PubMed ID: 11319616
[TBL] [Abstract][Full Text] [Related]
31. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
Alleva DG; Burger CJ; Elgert KD
J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
[TBL] [Abstract][Full Text] [Related]
32. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice.
Yim JH; Wu SJ; Casey MJ; Norton JA; Doherty GM
J Immunol; 1997 Feb; 158(3):1284-92. PubMed ID: 9013971
[TBL] [Abstract][Full Text] [Related]
33. [Augmentation of vaccination effects of PGE2-producing tumor cells by transfection with cytokine genes].
Ohiro Y
Hokkaido Igaku Zasshi; 1997 May; 72(3):273-84. PubMed ID: 9226467
[TBL] [Abstract][Full Text] [Related]
34. Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones.
Wortzel RD; Urban JL; Philipps C; Fitch FW; Schreiber H
J Immunol; 1983 May; 130(5):2461-6. PubMed ID: 6187859
[TBL] [Abstract][Full Text] [Related]
35. WEHI-164 clone 2F: in vitro antitumor effects of tumor necrosis factor and gamma-interferon.
Lattime EC; Stutman O
Nat Immun; 1992; 11(1):34-45. PubMed ID: 1611280
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
[TBL] [Abstract][Full Text] [Related]
38. Increase in tumor necrosis factor-alpha mRNA but not perforin mRNA expression in response to two newly characterized anti-LFA-1 monoclonal antibodies.
Hommel-Berrey G; Bochan M; Brahmi Z
Nat Immun; 1994; 13(6):301-14. PubMed ID: 7894201
[TBL] [Abstract][Full Text] [Related]
39. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
40. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
Weber JS; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5818-24. PubMed ID: 3139284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
